

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PF-0628 PCT	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 25499	International filing date (day/month/year) 29/10/1999	(Earliest) Priority Date (day/month/year) 29/10/1998
Applicant  INCYTE PHARMACEUTICALS, INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/25499

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17,18,20  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1 (partly) - 16 (partly) and 19 (partly)

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

Present claims 17,18 and 20 relate to a compound and method using the same defined by reference to a desirable characteristic or property, namely an agonist or antagonist effect with respect to the polypeptide of claim 1.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1(partly)-16(partly) and 19(partly)

A purified polypeptide comprising an amino acid sequence as shown in sequence No: 1 and the corresponding encoding polynucleotide comprising an nucleic acid sequence as shown in sequence No:3. Expression vectors comprising the polynucleotide and host cell comprising the expression vector as well as methods for detecting the polynucleotide. Polynucleotide which hybridizes or is complementary to the encoding polynucleotide as shown in sequence No: 3. Method for producing the polypeptide and an antibody which specifically binds to the latter. A pharmaceutical composition comprising the polypeptide and method of treatment using the same.

## 2. Claims: 1(partly)-16(partly) and 19(partly)

A purified polypeptide comprising an amino acid sequence as shown in sequence No: 2 and the corresponding encoding polynucleotide comprising an nucleic acid sequence as shown in sequence No:4. Expression vectors comprising the polynucleotide and host cell comprising the expression vector as well as methods for detecting the polynucleotide. Polynucleotide which hybridizes or is complementary to the encoding polynucleotide as shown in sequence No: 4. Method for producing the polypeptide and an antibody which specifically binds to the latter. A pharmaceutical composition comprising the polypeptide and method of treatment using the same.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25499

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/00 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YUASA T. ET AL.: "Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma"</p> <p>JAPANESE JOURNAL OF CANCER RESEARCH, vol. 89, September 1998 (1998-09), pages 879-882, XP000882554</p> <p>abstract</p> <p>page 879, column 1, line 1 -page 881, column 1, paragraph 1; figure 1</p> <p>---</p> <p>-/--</p>	1-16,19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

6 April 2000

Date of mailing of the international search report

07.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Muller-Thomalla, K

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25499

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL SEQUENCE DATABASE [Online]  EMBL, Heidelberg  Accession number: P30413,  1 April 1993 (1993-04-01)  KALLIN ET AL.: "Cloning of a growth  arrest-specific and transforming growth  factor beta-regulated gene, TI 1, from an  epithelial cell line"  XP002134989  abstract</p>	1-16,19
X	<p>---  DATABASE EMBL SEQUENCE DATABASE [Online]  EMBL, Heidelberg  Accessionnumber: P38573,  1 October 1994 (1994-10-01)  YU ET AL.: "Uroplakins Ia and Ib, two  major differentiation products of bladder  epithelium, belong to a family of four  transmembrane domain (4TM) proteins"  XP002134990  abstract</p>	1-16,19
A	<p>---  WRIGHT M D ET AL: "The ins and outs of  the transmembrane 4 superfamily"  IMMUNOLOGY TODAY,GB,ELSEVIER PUBLICATIONS,  CAMBRIDGE,  vol. 15, no. 12,  1 January 1994 (1994-01-01), pages  588-594, XP002066879  ISSN: 0167-5699  the whole document</p>	1-16,19
P,X	<p>---  WO 99 00408 A (INCYTE PHARMA INC ;CORLEY  NEIL C (US); SHAH PURVI (US); HILLMAN JE)  7 January 1999 (1999-01-07)  the whole document  -----</p>	1-16,19

### Information on patent family members

PCT/US 99/25499

Form PCT/ISA/210 (patent family annex) (July 1992)